相关实验视频

Updated: Jun 13, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

优化抗抑郁药的益处:在患有治疗耐药性抑郁症的身体活跃人群中,修达爆发刺激治疗的效果

Arthur R Chaves¹, Jennifer Cuda², Stacey Shim²

¹Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, 200 Lees Ave Building FHS, Ottawa, ON K1S 5S9, Canada; The Royal's Institute of Mental Health Research, 1145 Carling Ave, Ottawa, ON K1Z 7K4, Canada.

Journal of affective disorders

|September 11, 2024

概括

患有严重抑郁症 (MDD) 的身体活跃的个体表现出了theta爆发刺激 (TBS) 治疗的更好结果. 基线身体活动水平预测TBS接受MDD患者的治疗反应增强和症状减少更大.

科学领域:

神经科学是一个神经科学.
精神病学是一个精神病学.
行为科学行为科学

背景情况:

甲爆刺激 (TBS) 是对主要抑郁障碍 (MDD) 的有希望的治疗方法.
相当多的患者对TBS表现出不充分的反应,突出显示了需要增加治疗效果的因素.
身体活动因其情绪调节效应而得到认可,但其在调节对神经调节疗法 (如TBS) 的反应中的作用仍未得到充分探索.

研究的目的:

调查基线身体活动水平是否会影响TBS在治疗耐治疗MDD患者的疗效.
为了比较身体活跃的与接受TBS治疗的不活跃个体的抑郁症症状减少.

主要方法:

分析了一项随机对照试验,涉及43名患有MDD的参与者.
参与者根据基线国际体育活动问卷 (IPAQ) 成绩被分为身体活跃或不活跃.
抑郁症的严重程度使用汉密尔顿抑郁症评分表 (HRSD-17) 在基线,TBS治疗4周和6周测量.

主要成果:

时间和体力活动组之间的显著相互作用效应 (根据年龄和基线抑郁症进行调整) 表明治疗反应的差异.
在整个6周的TBS治疗期间,身体活跃的人始终报告了较低的抑郁症得分.
身体活跃的组在4周和6周表现出显著更大的改善,在6周内,更高比例的患者获得治疗反应 (≥50%的HRSD-17减少).

结论:

基线身体活动水平与患有重度抑郁症的患者对TBS的反应增强有关.
身体活跃的人可能从TBS治疗中获得更大的临床益处.
身体活动可能是一个有价值的因素,可以考虑优化MDD的TBS治疗结果.

关键词:

大型抑郁症主要是抑郁症.身体炼是一种体力炼.预测反应的预测因素泰达爆发刺激 (TBS) 的方法通过的磁性刺激 (TMS)抗治疗抑郁症的治疗方法

更多相关视频

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Continuous Theta Burst Stimulation of the Posterior Medial Frontal Cortex to Experimentally Reduce Ideological Threat Responses

Continuous Theta Burst Stimulation of the Posterior Medial Frontal Cortex to Experimentally Reduce Ideological Threat Responses

Published on: September 28, 2018

相关概念视频

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...